Healthpeak Properties (DOC) reported Q4 2025 FFO as adjusted of $0.47 per share and full-year FFO of $1.84, meeting the midpoint of guidance despite a 'historic life science environment.' The company demonstrated resilience through diversification, with Outpatient Medical achieving 91% occupancy and 3.9% same-store NOI growth, and Senior Housing delivering 12.6% same-store growth. However, the Life Science segment remains under pressure, reporting 77% occupancy and 1.5% same-store growth. For 2026, management guided FFO lower to $1.70-$1.74 per share, reflecting a 5-10% decline in Lab NOI. Strategic highlights include the announced spin-off of Senior Housing into a pure-play REIT (Janus Living) and the opportunistic acquisition of the 1.4M sq ft Gateway campus in South San Francisco. Management emphasized 'early signs of an inflection point' in life science capital markets but noted earnings will lag the recovery.
| Metric | Value | Change |
|---|---|---|
| Q4 FFO as Adjusted | $0.47 per share | In line with guidance midpoint |
| FY 2025 FFO as Adjusted | $1.84 per share | Met midpoint of original guidance range |
| FY 2025 AFFO | $1.69 per share | Reported |
| Q4 Same-Store Cash NOI Growth | 3.9% | Total portfolio growth |
| Outpatient Occupancy | 91% | Stable |
| Lab Occupancy | 77% | Inclusive of Gateway acquisition, depressed by >150 bps |
| Senior Housing Same-Store Growth | 12.6% | FY 2025, above high end of guidance |
| Net Debt to Adjusted EBITDA | 5.2x | Year-end 2025 |
Healthpeak announced the creation of a pure-play senior housing REIT (Janus Living) via an IPO. By contributing its entire senior housing portfolio in exchange for shares, Healthpeak retains significant ownership while unlocking value at a higher multiple. This allows Healthpeak to focus on its core Outpatient and Life Science segments while participating in the upside of the senior housing assets through a RIDEA structure where they remain the manager.
The company closed on the acquisition of the 1.4 million square foot Gateway campus in South San Francisco. Despite 500,000 sq ft of vacancy, management views this as a 'highly strategic' opportunity to gain market share in a prime submarket where they already control 210 acres (one-third of the land). The acquisition is expected to be breakeven in year one with high single-digit unlevered return potential as the market recovers.
Management pointed to 'early signs of an inflection point' in the life science sector, citing continued improvement in capital raising and M&A since Labor Day 2025. They noted that new deliveries will drop to zero for several years and some buildings are pivoting to alternative uses, suggesting a future supply constraint that benefits their portfolio.
Healthpeak is actively recycling capital, selling fully stabilized outpatient assets at low 6% cap rates to fund higher-upside investments. This strategy allows them to strengthen their life science portfolio (Gateway) and buy out JV partners in senior housing ($314M) without issuing equity at depressed prices.
For 2026, FFO guidance is set at $1.70-$1.74, a decrease from the $1.84 reported in 2025. This decline is driven by a forecasted 5-10% drop in Lab NOI, indicating the downturn is not yet over financially and that the recovery will be slow.
Management explicitly warned that 'earnings will lag the underlying recovery.' Even if occupancy improves, the financial benefits will be delayed due to the time required to sign leases and build out tenant improvements, prolonging the period of suppressed earnings.
The company faces $1.1 billion of refinancing activity in 2026, including $650 million of senior unsecured notes. Management acknowledged that borrowing costs are 'higher today than our in-place levels,' which will act as a drag on FFO.
Total lab occupancy sits at 77%, depressed by the Gateway acquisition. While management expects occupancy to improve by year-end 2026, the current low levels and the 'chunky' nature of life science leases (avg 60k sq ft) create volatility and risk regarding the timing of the rebound.
Overall: Management displayed a disciplined and confident tone regarding their diversified strategy, particularly the strength in Outpatient and Senior Housing. They were realistic but optimistic about the Life Science downturn, framing it as an opportunity to acquire assets at attractive basis. While prepared remarks were assertive about the 'building blocks of a recovery,' the Q&A session revealed a more cautious approach to timing, acknowledging the lag between occupancy and earnings.
Confidence: MEDIUM - Management is confident in the operational execution of Outpatient and Senior Housing and the strategic value of the Gateway acquisition. However, confidence regarding the immediate financial recovery of the Life Science segment is tempered by the explicit warning that 'earnings will lag the underlying recovery' and the guidance for lower FFO in 2026.
Management guided FFO in the range of $1.70 to $1.74 per share. This represents a decrease from 2025 levels, primarily driven by a 5-10% decline in Lab NOI and the impact of refinancing debt at higher rates.
Total portfolio same-store NOI growth is forecasted to be in the range of down 1% to up 1%. This assumes Outpatient growth of 2-3%, Lab decline of 5-10%, and Senior Housing growth of 8-12%.
Management expects total lab occupancy to improve by year-end 2026 from the 77% reported at year-end 2025, assuming continued improvement in capital markets.
Hedging & Uncertainty: Management employed significant hedging regarding the Life Science recovery timeline. Phrases like 'early signs of an inflection point,' 'optimistic that that will continue,' and 'best guess' regarding the lease-up period suggest they see positive trends but are unwilling to guarantee the timing. They also used temporal hedges such as 'over the next two to three years' when discussing the upside from the Gateway acquisition and senior housing turnarounds. This hedging reveals a management team that is encouraged by macro trends but acutely aware of the execution risks and timing lags inherent in their current portfolio.
The building blocks of a recovery are in place. - Scott Brinker, CEO
Naturally, earnings will lag the underlying recovery. - Scott Brinker, CEO
We're in a position to opportunistically acquire assets with a lot of upside. - Scott Brinker, CEO
We do think total occupancy by year-end '26 should improve. - Scott Brinker, CEO
The reduction in earnings is attributable to the loss of occupancy in lab which, as we have noted, has a lagging impact on earnings. - Kelvin Moses, CFO
Analyst Sentiment: Analysts were focused on the mechanics of the Lab recovery, the specific underwriting of the Gateway deal, and the structure of the Janus Living IPO. There was a degree of skepticism regarding the timing of the rebound, with questions focusing on the 'lag' between occupancy and earnings.
Management Responses: Management was transparent and detailed, breaking down the specific drivers of the earnings lag (security deposits, lease terms, TI costs). They defended the Gateway acquisition as a unique opportunity with a 'breakeven year one yield' and high upside potential, while remaining cautious about committing to specific timelines for the lab recovery.
Lab Recovery Timing: Analysts pressed for details on the cadence of occupancy recovery and the 'watch list' for tenants. Management responded that capital markets activity has improved and the watch list has reduced, but earnings will lag occupancy gains.
Gateway Acquisition: Questions focused on the vacancy risk and underwriting assumptions. Management emphasized their dominant market position in South San Francisco and the opportunistic nature of the buy, noting it was a 'breakeven year one' deal.
Janus Living IPO: Analysts sought details on the structure and CapEx. Management clarified that all senior housing assets (including CCRCs) will be contributed and that they will remain the manager, with the IPO timing dependent on the SEC process.
Healthpeak Properties is a high-quality diversified healthcare REIT currently facing a cyclical downturn in its Life Science segment. The company is taking the right strategic steps to navigate this environment, including spinning off its Senior Housing assets (Janus Living) to unlock value and recycling capital into opportunistic acquisitions like the Gateway campus. While the Outpatient segment provides a stable foundation (91% occupancy), the 2026 guidance for declining FFO ($1.70-$1.74) reflects the severity of the Lab headwinds. Management's confidence in a '2026 bottom' is plausible but relies on a sustained recovery in biotech capital markets. The stock is suitable for investors with a long-term horizon who believe in the Bay Area life science story, but near-term earnings pressure and the execution risk associated with the Janus Living IPO warrant a HOLD rating until the recovery is more evident.
The transcript suggests a broader thawing in the biotech capital markets, which is a leading indicator for life science real estate demand. Management noted 'continued improvement in capital raising and M&A' since Labor Day 2025 and stated that 'new deliveries will soon go to zero.' This indicates a supply-demand imbalance that could benefit the entire sector in the coming years, as new supply dries up while capital availability returns.